查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
难治型忧郁症(TRD)治疗的全球市场-成长，未来展望，竞争分析(2022年～2030年)
市场调查报告书
商品编码
1192922

难治型忧郁症(TRD)治疗的全球市场-成长，未来展望，竞争分析(2022年～2030年)

Treatment-Resistant Depression (TRD) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

全球难治型忧郁症(TRD)治疗的市场规模，预计从2022年到2030年的预测期间内预计以3.6％的年复合成长率成长。对忧郁症及焦虑症的发病率增加，精神障碍的治疗所使用的药物的合适偿付情境，推动市场成长。

本报告提供全球难治型忧郁症(TRD)治疗市场相关调查分析，市场动态，市场分析，企业简介等系统性资讯。

目录

第1章 序文

  • 报告的说明
    • 报告的目的
    • 目标受众
    • 主要的产品
  • 市场区隔
  • 调查手法
    • 阶段Ⅰ-2次调查
    • 阶段Ⅱ-1次调查
    • 阶段Ⅲ-专家的审查
    • 假设
    • 所采用的方法

第2章 摘要整理

  • 市场概述:全球难治型忧郁症(TRD)治疗市场
  • 全球难治型忧郁症(TRD)治疗市场(100万美元)(2021年):各类药物
  • 全球难治型忧郁症(TRD)治疗市场(100万美元):各地区
  • 富有魅力的投资提案(2021年):各地区

第3章 难治型忧郁症(TRD)治疗市场:竞争分析

  • 主要的难治型忧郁症(TRD)治疗市场供应商的市场定位
  • 难治型忧郁症(TRD)治疗市场供应商采用的策略
  • 主要的产业策略
  • 阶层分析:2021年和2030年的比较

第4章 难治型忧郁症(TRD)治疗市场:常量分析和市场动态

  • 简介
  • 全球难治型忧郁症(TRD)治疗市场金额(100万美元)(2020年～2030年)
  • 市场动态
    • 推动市场要素
    • 阻碍市场要素
    • 主要课题
    • 主要的机会
  • 促进因素与阻碍因素的影响分析
  • See-Saw分析

第5章 难治型忧郁症(TRD)治疗市场，美金(100万)(2020年～2030年):各类药物

  • 市场概要
  • 成长和收益分析::2021年和2030年的比较
  • 市场区隔
    • 选择性血清素再回收抑制剂(SSRI)
    • 单胺氧化酵素抑制剂(MAOI's)
    • 三环抗忧郁药物
    • 血清素1A受体促效剂
    • 艾氯胺酮鼻子喷雾

第6章 北美的难治型忧郁症(TRD)治疗市场，美金(100万)(2020年～2030年)

第7章 英国及欧洲联盟的难治型忧郁症(TRD)治疗市场，美金(100万)(2020年～2030年)

第8章 亚太地区的难治型忧郁症(TRD)治疗市场，美金(100万)(2020年～2030年)

第9章 南美的难治型忧郁症(TRD)治疗市场，美金(100万)(2020年～2030年)

第10章 中东及非洲的难治型忧郁症(TRD)治疗市场，美金(100万)(2020年～2030年)

第11章 企业简介

  • Bristol Myers Squibb Company
  • Eli Lilly & Company
  • Janssen Pharmaceutcials, Inc.
  • Mylan Pharmaceutcials, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Valeant Pharmaceuticals International
  • Validus Pharmaceuticals LLC
  • Wyeth
Product Code: 137370-08-22

Industry Outlook

The treatment-resistant depression treatment market is exhibiting good growth at a compounded annual growth rate (CAGR) of 3.6% during the forecast period from 2022 to 2030. Depression is the most common mental disorder affecting approximately 300 million people worldwide. The prevalence rate is high in women in comparison to men. In the last 2 decades there has been significant rise in the number of ailing patients showing resistance to first line therapy drugs for treating depression. Recently USFDA gave approval to Esketamine nasal sprays for treating TRD. Currently AXS-05 drug developed by Axsome Therapeutics, Inc., is under phase III clinical trial investigation for its application in treating TRD.

Recent USFDA approval of Spravato (esketamine nasal spray) will register impressive growth during the forecast period

In one third of the patients suffering with depression treatment resistant in encountered when patients fail to respond to first line therapy drugs. The underlying factor responsible for this resistance is not known, accurate diagnosis and identification of possible cormorbid condition determines treatment-resistant depression (TRD) in ailing patients worldwide. The treatment regimen followed is prescribing drugs such as SSRI's, MAOI's, tricyclic antidepressant and serotonin 1A receptor agonist for treating TRD. Increasing the dose of prescribed medicine to maximum toleration level, combination of antidepressants or switching to different class of antidepressant is the best possible and conventional method adopted in its treatment globally. Recently USFDA has approved Esketamine nasal spray (Spravato) developed by Janssen Pharmaceutical, Inc., as the novel prescription drug for treating TRD in conjunction with an oral antidepressant. Researchers anticipate its faster adoption rate owing to its excellent pharmacokinetic and pharmacodynamic profile observed during clinical trial investigation.

Growing incidence of depression and anxiety to drive the market growth in North America region

North America with a share of 34.2% is dominating the regional segment for treatment-resistant depression treatment market. According to the latest statistics provided by Center for Disease Control and Prevention (CDC) the incidence rate of suicidal deaths is 14.5 per 100,000 people in the United States. Affordable reimbursement scenario for the drugs employed in treating mental disorders further propels the market growth in the region. In the second place is Europe representing a market share of 30.5% owing to the domicile of key players such as Novartis AG, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Mylan Pharmaceuticals, Inc. etc. Asia Pacific is currently holding 17.3% market share on account of rising prevalence of mental disorders, effective implementation of treatment regiment to treat depression and suicidal tendency across all age groups.

Pharmaceutical companies manufacturing drugs for the treatment regimen of treatment-resistant depression are Bristol Myers Squibb Company, Eli Lilly & Company, Janssen Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Valeant Pharmaceuticals International, Validus Pharmaceuticals LLC and Wyeth.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Treatment-Resistant Depression (TRD) Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Treatment-Resistant Depression (TRD) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Selective Serotonin Reuptake Inhibitors (SSRI's)

Monoamine Oxidase Inhibitors (MAOI's)

Tricyclic Antidepressant

Serotonin 1A Receptor Agonist

Esketamine Nasal Spray

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Treatment-Resistant Depression (TRD) Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Treatment-Resistant Depression (TRD) Treatment market?

Which is the largest regional market for Treatment-Resistant Depression (TRD) Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Treatment-Resistant Depression (TRD) Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Treatment-Resistant Depression (TRD) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Treatment-Resistant Depression (TRD) Treatment Market
  • 2.2. Global Treatment-Resistant Depression (TRD) Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Treatment-Resistant Depression (TRD) Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Treatment-Resistant Depression (TRD) Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Treatment-Resistant Depression (TRD) Treatment Market Vendors
  • 3.2. Strategies Adopted by Treatment-Resistant Depression (TRD) Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Treatment-Resistant Depression (TRD) Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Treatment-Resistant Depression (TRD) Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Selective Serotonin Reuptake Inhibitors (SSRI's)
    • 5.3.2. Monoamine Oxidase Inhibitors (MAOI's)
    • 5.3.3. Tricyclic Antidepressant
    • 5.3.4. Serotonin 1A Receptor Agonist
    • 5.3.5. Esketamine Nasal Spray

6. North America Treatment-Resistant Depression (TRD) Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Treatment-Resistant Depression (TRD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)

7. UK and European Union Treatment-Resistant Depression (TRD) Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Treatment-Resistant Depression (TRD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)

8. Asia Pacific Treatment-Resistant Depression (TRD) Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Treatment-Resistant Depression (TRD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)

9. Latin America Treatment-Resistant Depression (TRD) Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Treatment-Resistant Depression (TRD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)

10. Middle East and Africa Treatment-Resistant Depression (TRD) Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3.Treatment-Resistant Depression (TRD) Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Treatment-Resistant Depression (TRD) Treatment Market: By Drug Class, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Bristol Myers Squibb Company
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Eli Lilly & Company
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Janssen Pharmaceutcials, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Mylan Pharmaceutcials, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Novartis AG
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Otsuka Pharmaceutical Co., Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Pfizer, Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Valeant Pharmaceuticals International
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Validus Pharmaceuticals LLC
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Wyeth
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 U.S. Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Canada Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 7 UK Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 8 Germany Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 9 Spain Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 10 Italy Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 11 France Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 13 Asia Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 China Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 15 Japan Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 16 India Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Australia Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 18 South Korea Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 19 Latin America Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 20 Brazil Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 21 Mexico Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 24 GCC Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 25 Africa Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Treatment-Resistant Depression (TRD) Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Treatment-Resistant Depression (TRD) Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Treatment-Resistant Depression (TRD) Treatment Market: Quality Assurance
  • FIG. 5 Global Treatment-Resistant Depression (TRD) Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Treatment-Resistant Depression (TRD) Treatment Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Treatment-Resistant Depression (TRD) Treatment Market, 2021
  • FIG. 8 Market Positioning of Key Treatment-Resistant Depression (TRD) Treatment Market Players, 2021
  • FIG. 9 Global Treatment-Resistant Depression (TRD) Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Treatment-Resistant Depression (TRD) Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 11 U.S. Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 France Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 China Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 India Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Treatment-Resistant Depression (TRD) Treatment Market (US$ Million), 2020 - 2030